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Abstract
Background:  Accurate assessment of HER-2/neu  status is crucial for proper prognostic
information and to offer direct appropriate treatment for breast cancer patients. Next to
immunohistochemistry (IHC) to evaluate HER2 protein overexpression, a second line gene
amplification test is generally deemed necessary for cases with equivocal protein expression.
Recently, a new PCR based test, called Multiplex Ligation-dependent Probe Amplification (MLPA),
was introduced as a simple and quick method to assess HER-2/neu gene amplification status in
invasive breast cancer. MLPA was previously shown to correlate well with IHC and in situ
hybridization (ISH), but a low tumor percentage in the tissue tested could negatively affect the
accuracy of MLPA results.
Methods: To examine this, MLPA was repeated in 42 patients after serial H&E section guided
manual dissection with a scalpel and after laser microdissection of the tumor.
Results: Both dissection techniques led to higher HER2 gene copy number ratios and thereby
made MLPA more quantitative. Concordance between MLPA and ISH improved from 61% to 84%
after manual microdissection and to 90% after laser microdissection.
Conclusion: Manual and laser microdissection similarly increase the dynamic range of MLPA copy
number ratios which is a technical advantage. As clinically a dichotomization between normal and
amplified suffices and MLPA is relatively unsensitive to tumor content, microdissection before
MLPA may not be routinely necessary but may be advisable in case of very low tumor content
(≤30%), when MLPA results are equivocal, or when extensive ductal carcinoma in situ is present.
Since differences between manual and laser microdissection were small, less time consuming
manual microdissection appears to be sufficient.
Background
HER-2/neu is a proto-oncogene located on chromosome
17q21 encoding a 185 kD transmembrane protein that is
involved in signal transduction [1,2]. HER2 belongs to the
human epidermal growth factor receptor (EGFR) family
and is amplified in about 10–20% of breast carcinomas
causing an increased expression of its protein [3-5].
Patients having this overexpression respond well to treat-
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ment with trastuzumab, a recombinant humanized mon-
oclonal anti-HER2 antibody [6,7]. Since the costs for
trastuzumab therapy are high and side effects are signifi-
cant, accurate selection of eligible patients for this therapy
is very important. Furthermore, amplification of HER2
has also been shown to correlate with poor prognosis [8]
and with resistance to conventional adjuvant chemother-
apy and tamoxifen [9-13]. With the recognition of its
prognostic, predictive and therapeutic implications,
assessment of HER2 status has now become of major
importance in clinical practice for breast cancer patients.
At present, HER2 status is most commonly assessed by
immunohistochemistry (IHC) and/or gene amplification
tests such as fluorescence in situ hybridization (FISH) [14-
16] or chromogenic in situ hybridization (CISH) [17].
However, these techniques can only be assessed semi-
quantitatively, and amplification detection by easier
quantitative PCR techniques has therefore been proposed
as an alternative. One of the newly introduced techniques
for detection of HER2 amplification is multiplex ligation-
dependent probe amplification (MLPA)[18]. In MLPA
reactions, mixes composed of up to 45 probes can be used
which makes it easy to quantitatively assess the copy
number of different genes simultaneously, allowing for
multiple target probes and controls. Moreover, this tech-
nique requires only minute quantities of short DNA frag-
ments, which makes it very suitable for DNA isolated
from paraffin embedded material. In previous studies
using whole tissue sections we obtained very promising
results with MLPA in comparison with IHC [19], FISH and
CISH [20]. However, the dynamic range of MLPA copy
number ratios was lower than with FISH. Furthermore,
although results showed that amplification could even be
detected in cases with a tumor percentage lower than
10%, the sensitivity of MLPA in these cases will depend on
the degree of amplification, so lower levels of amplifica-
tions can be missed in case of a low tumor percentage.
Laser-based tissue microdissection can potentially solve
this issue [21]. However, it is relatively time consuming
and therefore not very attractive as a routine test, so the
question is whether faster H&E guided manual microdis-
section with a scalpel ("mesodissection") would suffice.
The aim of this study was therefore to determine to which
extent manual and laser microdissection improve the
dynamic range of copy number ratios and the sensitivity
for amplification detection of HER2 by MLPA.
Methods
Patient material
Resection specimens were chosen from a previously used
series of 423 consecutive invasive breast cancer patients
collected between November 2004 and June 2006 at the
Department of Pathology of the University Medical Cen-
tre in Utrecht. This study using left over material was
approved by the Tissue Science Committee of the UMC
Utrecht. All tissue samples had already been analyzed by
MLPA and IHC and a smaller fraction by in situ hybridiza-
tion (ISH) for HER2 amplification status[20]. From this
series, thirty one samples with low tumor content (< 60%)
and/or discrepant results between MLPA and IHC/ISH
were selected to study whether concordance with ISH (as
gold standard) would improve after microdissection. In
addition, 11 MLPA-amplified cases were selected to exam-
ine whether the dynamic range of HER2 gene copy
number ratios increases after microdissection. Tumor per-
centages were between 10 and 90%. Although MLPA was
shown to work well on biopsies in our previous study[20],
we selected for this study only resection specimens to be
sure to have sufficient material after recutting paraffin
blocks.
Microdissection
Microdissection was performed on 4 μm thick paraffin
sections. For manual microdissection, the relevant area
was scraped off with a scalpel by comparing with a serial
H&E stained slide where tumor tissue was marked and
presence of ductal carcinoma in situ (DCIS) was noted. For
laser microdissection, sections were baked at 56°C for 1
hour, deparaffinized in xylene for 10 minutes and rehy-
drated through graded alcohols (100%, 85% and 70% for
1 minute each). After staining with haematoxylin for 5
seconds, slides were rinsed in water and dipped in eosin
for 5 seconds. Finally, slides were dehydrated in 100%
ethanol for 1 minute and air dried. At this point PALM
Liquid Cover Glass (LiquidCoverglass, PALM AG, Bern-
ried, Germany) was applied by aerosol to improve mor-
phology and to allow larger tissue areas to be laser
pressure-catapulted [22], and sections were air dried for at
least 30 minutes. A microdissection system with UV laser
(PALM Microlaser Technologies AG, Bernried, Germany)
was used to separate between 3 and 40 square mm of inva-
sive tumor groups from their surrounding tissue. Subse-
quently, these groups were catapulted by laser pressure
catapulting into a cap of a common microfuge tube mois-
tened with a drop of mineral oil.
Multiplex ligation-dependent Probe Amplification (MLPA)
DNA from dissected tumor was isolated by 1 hour incuba-
tion in proteinase K (10 mg/ml; Roche, Almere, Nether-
lands) at 56°C followed by boiling for 10 minutes. This
DNA solution (50–100 μl) was, after centrifugation, used
in the MLPA analysis according the manufacturers'
instructions, using the P004-A1 HER2 kit (MRC Holland,
Amsterdam, The Netherlands). This kit contains 3 probes
for the HER2 gene, 11 other chromosome 17 control
probes, and 25 control probes located on other chromo-
somes. Details of the probes in this kit can be found at
http://www.mrc-holland.com. All tests were performed inBMC Cancer 2009, 9:4 http://www.biomedcentral.com/1471-2407/9/4
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duplicate in an ABI 9700 PCR machine. PCR products
were analyzed on an ABI310 capillary sequencer (Applied
Biosystems, Foster City, CA, USA). HER2 gene copy
number was determined by calculating the mean ratio of
the HER2 probe peaks with the two previous peaks and
the two following peaks. The mean of all three HER2
probe peaks in duplicate (6 values) was calculated. If this
value was below 1.5 (cut-off value) the test was scored
non-amplified, values 1.5–2.0 were scored as a low level
amplification, and values > 2 as HER2 amplified.
Statistical Analysis
Comparison between copy number ratios before and after
microdissection were analyzed by a paired-samples t-test
after testing for normal distribution. Association between
difference in copy number ratio before and after microdis-
section and tumor percentage was tested by subtracting
ratios and plotting them against tumor percentage, fol-
lowed by linear regression analysis. All tests were done
with SPSS software, regarding two-sided p-values < 0.05 as
significant.
MLPA values (copy number ratios) for 11 HER2 amplified breast cancer cases before (no MD) and after manual and laser  microdissection (MD) Figure 1
MLPA values (copy number ratios) for 11 HER2 amplified breast cancer cases before (no MD) and after man-
ual and laser microdissection (MD).BMC Cancer 2009, 9:4 http://www.biomedcentral.com/1471-2407/9/4
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Results
Figure 1 shows the MLPA copy number ratios for 11 MLPA
amplified cases before and after microdissection. Manual
microdissection led to an increase in measured HER2
gene copy number (p = 0.001), with in most cases a fur-
ther increase after laser microdissection (p = 0.007 vs non-
dissected MLPA), with no significant difference between
manual and laser microdissection (p = 0.055). In two
cases the presence of DCIS may have caused the laser
microdissection value to be lower than the manual micro-
dissection value. Figure 2 shows that there was no associ-
ation between copy number ratios before and after
microdissection and tumor percentage.
Table 1 shows the amplification status of 42 breast cancer
patients without and after manual and laser microdissec-
tion, in comparison with in situ hybridization (ISH)
results.
Tables 2, 3 and 4 show the concordance between ISH and
MLPA without, after manual- and laser microdissection,
respectively, with concordance percentages of 61%, 84%
and 90%, respectively. For 11/17 patients (65%) that
showed discrepancies between MLPA (low or high level)
amplified and IHC/ISH, manual or laser microdissection
was able to adjust the original MLPA score (based on the
whole slide). For 8/11 of these cases (73%), there was no
Scatter plots showing no association between the MLPA ratio difference before (no MD) and after manual- or laser microdis- section (MD) on the one hand and tumor percentage of the sample on the other Figure 2
Scatter plots showing no association between the MLPA ratio difference before (no MD) and after manual- or 
laser microdissection (MD) on the one hand and tumor percentage of the sample on the other.
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Table 1: HER-2/neu amplification status by multiplex ligation-dependent probe amplification (MLPA) of 42 breast cancer patients in 
undissected sections and after manual and laser microdissection, in comparison with in situ hybridization and immunohistochemistry.
MLPA
Case number IHC ISH Undissected Manual MD Laser MD DCIS Tumor %
10 N A 1 1 1 Y e s 3 0
2 0 NA 1 1 1 30
30 N A 1 1 1 Y e s 1 0
4 2 NA 1 1 1 10
52 N A 1 1 1 Y e s 7 0
62 N A 1 1 2 Y e s 7 0
7 2 NA 1 1 1 50
8 2 NA 1 1 1 70
9 2 NA 1 1 1 70
10 2 NA 1 1 1 60
11 2 NA 1 1 1 30
12 2 NA 1 1 1 60
13 1 LA 2 2 2 70
14 2 A 2 3 3 80
15 2 A 2 2 3 Yes 80
16 3 A 2 2 3 80
17 2 LA 2 2 3 80
18 0 NA 2 1 1 Yes 90
19 0 NA 2 1 1 80
20 1 A 2 3 3 70
21 1 LA 2 3 2 Yes 50
22 1 NA 2 2 1 Yes 80
23 1 NA 2 1 1 Yes 10
24 1 NA 2 1 1 Yes 60
25 0 NA 3 1 1 60
26 0 NA 3 1 1 80
27 1 A 3 3 3 70
28 1 NA 3 3 3 Yes 30
29 3 A 3 3 3 50
30 1 A 3 3 3 80
31 2 A 3 3 3 Yes 70
32 3 A 3 3 3 Yes 80
33 3 A 3 3 3 20
34 3 A 3 3 3 70
35 3 A 3 3 3 80
36 3 A 3 3 3 70
37 3 A 3 3 3 30
38 3 A 3 3 3 70
39 3 A 3 3 3 60
40 2 A 3 3 3 Yes 40
41 3 A 3 3 3 Yes 20
42 3 A 3 3 3 10
IHC = immunohistochemistry (Hercep test), ISH = in situ hybridization, NA = non-amplified, LA = low-level amplified, A = amplified, MD = 
microdissection, DCIS = ductal carcinoma in situ
Table 2: Concordance between HER2 ISH and MLPA without microdissection in 31 invasive breast cancer cases
MLPA
Not amplified Low level amplified Amplified Total
ISH Not amplified 12 5 3 20
Low level amplified 0 3 0 3
Amplified 0 4 4 8
Total 12 12 7 31BMC Cancer 2009, 9:4 http://www.biomedcentral.com/1471-2407/9/4
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obvious difference between laser microdissection and
manual microdissection. However, in 3/11 cases (27%)
only laser microdissection was able to change the MLPA
outcome. Figure 3 shows that for all but one (11/12)
MLPA non-amplified (9 of them IHC equivocal) cases, the
MLPA score was unchanged after manual- and laser
microdissection. For this case (tumor percentage 70%) the
MLPA score became low level amplified after laser micro-
dissection.
12/31 (39%) samples contained DCIS. In 4/12 (33%) of
these cases this could have contributed to biased MLPA
results, which was circumvented by manual and/or laser
microdissection.
MLPA values (copy number ratios) for 30 patients before (no MD) and after manual and laser microdissection (MD) Figure 3
MLPA values (copy number ratios) for 30 patients before (no MD) and after manual and laser microdissection 
(MD). The vertical lines show the cut-off values (1.50 and 2.00) between an MLPA non-amplified, low-level amplified, and 
amplified outcome.
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As this paper is in part focussed on discrepant results we
also evaluated concordance between the three HER-2/neu
probes included in the MLPA kit in individual cases, as
well as the variation of the control probes between the
duplicate assessments. There was full (amplification sta-
tus) concordance for the three probes in 71% of cases. In
the other 29% of cases, the discordant probe ratio value
was close but just across the cut-off values. In 62% and
38% of the cases with a discordant probe this concerned a
discrepancy between non-amplified/low level amplified
and low level/high level amplification, respectively. The
third probe accounted for most discordance (48% of dis-
crepancies), possibly due to its lower ratio values com-
pared to the other probes.
Between duplicate measurements, the three probes per-
formed similarly with discrepancies of 9.5%, 11% and
12%, respectively.
As to the 25 reference probes in the P004-A1 MLPA kit
(data from the whole original group of unselected
patients), amplifications were found in 0.6–10.8% of the
patients. High level amplifications of the control probes
were very rare, varying between 0 and 2%. Low level
amplifications were however common for some probes
(range 0.6–9.1%) with 5/25 probes (HIPK3, STCH,
CCNB1, PTPN1 and IER3) showing low level amplifica-
tion in more than 5% of patients.
Discussion
The goal of our study was to examine the effect of manual
and laser microdissection on HER2 MLPA copy number
ratios of 42 breast cancer samples with low tumor percent-
age and/or discrepancies between MLPA on the one hand
and IHC and/or ISH on the other. As we wanted to simu-
late daily practice, we applied a crude method to obtain
DNA and did not isolate DNA with more refined meth-
ods. We have as yet no indication that a more precise DNA
isolation improves HER2 amplification detection by the
MLPA technique, but we agree we cannot exclude that.
This will be the subject of further research.
Copy number ratios increased after manual microdissec-
tion and even more after laser microdissection, indicating
that the dynamic range of MLPA increases when the test
sample is enriched for tumor cells, making this technique
more quantitative. Nevertheless, the highest ratio
observed was about 10, which is less than generally
observed with FISH. The fact that higher ratios are not
observed even after maximal enrichment for tumor cells is
probably inherent to the MLPA technique. However, since
the copy number ratio, once amplified, does not further
contribute to clinical decision making this is not at all a
problem in daily practice.
We showed in Figure 2 that there was no association
between copy number ratios before and after microdissec-
tion and tumor percentage. This can be explained by the
presence of background signal from non-tumorous cells
(infiltrate/benign breast) and DCIS in non-dissected sam-
ples. DCIS can cause a false higher copy number ratio that
becomes lower after performing microdissection to
exclude the DCIS.
Correlation between MLPA and ISH (as gold standard)
improved after manual or laser microdissection, indicat-
ing that enrichment for tumor cells increases reliability of
MLPA. However, manual or laser microdissection had
only an effect on MLPA score in 1/12 non-amplified
patients. In this study and in our previous study amplifi-
Table 3: Concordance between HER2 ISH and MLPA after manual microdissection in 31 invasive breast cancer cases
MLPA
Not amplified Low level amplified Amplified Total
ISH Not amplified 18 1 1 20
Low level amplified 0 2 1 3
Amplified 0 2 6 8
Total 18 5 8 31
Table 4: Concordance between HER2 ISH and MLPA after laser microdissection in 31 invasive breast cancer cases
MLPA
Not amplified Low level amplified Amplified Total
ISH Not amplified 18 1 1 20
Low level amplified 0 2 1 3
Amplified 0 0 8 8
Total 18 3 10 31BMC Cancer 2009, 9:4 http://www.biomedcentral.com/1471-2407/9/4
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cation was detected by MLPA even in cases with a tumor
percentage below 10% [20], indicating that MLPA is rela-
tively insensitive to tumor percentage (although sensitiv-
ity of MLPA will likely depend on the degree of
amplification in case of low tumor percentage) and that
routine microdissection may not be required in daily
practice. However, also some undissected samples with
high tumor % and without DCIS showed amplification by
MLPA that could not be confirmed by ISH. Although we
cannot exclude that tumor heterogeneity plays a role here,
MLPA may occasionally provide false positive results. This
concerned however only 6/423 cases, so the rate of false
positivity may only be in the range of 1%.
Nevertheless, patients with especially a low level amplifi-
cation MLPA result seem to benefit most from microdis-
section. Manual microdissection seems to suffice in most
cases as differences between manual and laser microdis-
section results were small.
The amplification and overexpression of HER2 is seen
more frequently in DCIS (50–60%) [23] than in invasive
ductal carcinoma of the breast (10–20%) and the pres-
ence of DCIS can thereby bias MLPA results. In our study
the presence of DCIS probably contributed to biased
MLPA outcome as circumvented by manual and/or laser
microdissection in 33% (4/12) of (selected) cases. There-
fore, if MLPA results are equivocal or extensive DCIS is
present, we advise to perform careful manual (or laser)
microdissection before MLPA or to use CISH/FISH as an
alternative.
When comparing performance of the three HER2 probes,
the third probe showed most frequently a discordance
with the other two probes, possibly due to its lower ratio
values. In duplicate assessments, however, all probes per-
formed about equally well, indicating that reproducibility
is good.
Some of the 25 reference probes that were originally cho-
sen for their supposed lack of amplification in breast can-
cer were nevertheless amplified. Therefore, at least the five
probes (HIPK3, STCH, CCNB1, PTPN1 and IER3) that
were (low level) amplified in more than 5% of cases may
need to be replaced.
Conclusion
MLPA is a fast, accurate and cheap method to detect breast
cancer HER-2/neu  amplification in small quantities of
DNA extracted from paraffin blocks. Amplification can be
detected even in cases with very low tumor percentages.
Manual or laser microdissection of breast cancer slides
before HER2 MLPA may hence not be routinely necessary.
However, the dynamic range of the technique improves
after manual and laser microdissection and may therefore
at least be advisable in case of very low tumour content
(≤30%), when the MLPA outcome is equivocal or when
extensive DCIS is present. Since differences between man-
ual and laser microdissection were small, less time con-
suming manual microdissection seems to suffice then.
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